Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Buy
83
TAK Quote, Financials, Valuation and Earnings
Last price:
$18.49
Seasonality move
:
-3.96%
Day range:
$18.36 - $18.50
52-week range:
$12.99 - $18.50
Dividend yield:
3.58%
P/E ratio:
76.66x
P/S ratio:
1.96x
P/B ratio:
1.20x
Volume:
3.1M
Avg. volume:
3.3M
1-year change:
35.54%
Market cap:
$58.3B
Revenue:
$30.1B
EPS (TTM):
$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$184.2T | -- | 1.97% | -- | $19.07 |
|
HALO
Halozyme Therapeutics, Inc.
|
$446.1M | $2.20 | 44.12% | 89.01% | $78.00 |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
PTGX
Protagonist Therapeutics, Inc.
|
$14.9M | -$0.54 | -23.52% | -191.66% | $101.92 |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$18.46 | $19.07 | $58.3B | 76.66x | $0.32 | 3.58% | 1.96x |
|
HALO
Halozyme Therapeutics, Inc.
|
$79.44 | $78.00 | $9.3B | 16.70x | $0.00 | 0% | 8.02x |
|
PPTDF
PeptiDream Inc.
|
$10.42 | -- | $1.3B | 13.79x | $0.00 | 0% | 11.22x |
|
PTGX
Protagonist Therapeutics, Inc.
|
$81.49 | $101.92 | $5.1B | 128.68x | $0.00 | 0% | 24.99x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.44 | -- | $492.3M | -- | $0.00 | 0% | 2.47x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
38.84% | -0.837 | 62.88% | 0.53x |
|
HALO
Halozyme Therapeutics, Inc.
|
74.99% | -1.035 | 17.53% | 1.26x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.074 | 8.66% | 4.05x |
|
PTGX
Protagonist Therapeutics, Inc.
|
1.64% | -0.620 | 0.26% | 12.83x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
48.47% | 1.070 | 73.82% | 1.61x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$4.2B | $1.2B | 0.98% | 1.63% | 16% | $822.4M |
|
HALO
Halozyme Therapeutics, Inc.
|
$281.3M | $217.9M | 30.69% | 139.43% | 61.51% | $175.6M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
PTGX
Protagonist Therapeutics, Inc.
|
$4.4M | -$46.4M | 7.03% | 7.15% | -985.17% | -$2M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$37.1M | -$8.9M | -9.66% | -19.06% | -17.59% | -$1M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
Takeda Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns TAK or HALO?
Halozyme Therapeutics, Inc. has a net margin of 8.71% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 49.46%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 1.63% beat Halozyme Therapeutics, Inc.'s return on equity of 139.43%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.54.43% $0.21 $79.7B HALOHalozyme Therapeutics, Inc.79.39% $1.43 $2B -
What do Analysts Say About TAK or HALO?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $19.07, signalling upside risk potential of 3.28%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $78.00 which suggests that it could fall by -1.81%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Halozyme Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 HALOHalozyme Therapeutics, Inc.4 2 1 -
Is TAK or HALO More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.014, which suggesting that the stock is 98.579% less volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.227%.
-
Which is a Better Dividend Stock TAK or HALO?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 3.58%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or HALO?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.7B, which are larger than Halozyme Therapeutics, Inc. quarterly revenues of $354.3M. Takeda Pharmaceutical Co., Ltd.'s net income of $673.3M is higher than Halozyme Therapeutics, Inc.'s net income of $175.2M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 76.66x while Halozyme Therapeutics, Inc.'s PE ratio is 16.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.96x versus 8.02x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.96x 76.66x $7.7B $673.3M HALOHalozyme Therapeutics, Inc.8.02x 16.70x $354.3M $175.2M
-
Which has Higher Returns TAK or PPTDF?
PeptiDream Inc. has a net margin of 8.71% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of -25.38%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 1.63% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.54.43% $0.21 $79.7B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About TAK or PPTDF?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $19.07, signalling upside risk potential of 3.28%. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is TAK or PPTDF More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.014, which suggesting that the stock is 98.579% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.573, suggesting its less volatile than the S&P 500 by 42.666%.
-
Which is a Better Dividend Stock TAK or PPTDF?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 3.58%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or PPTDF?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.7B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Takeda Pharmaceutical Co., Ltd.'s net income of $673.3M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 76.66x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.96x versus 11.22x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.96x 76.66x $7.7B $673.3M PPTDFPeptiDream Inc.11.22x 13.79x $29.3M -$7.4M
-
Which has Higher Returns TAK or PTGX?
Protagonist Therapeutics, Inc. has a net margin of 8.71% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of -834.87%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 1.63% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.54.43% $0.21 $79.7B PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M -
What do Analysts Say About TAK or PTGX?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $19.07, signalling upside risk potential of 3.28%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $101.92 which suggests that it could grow by 25.07%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Takeda Pharmaceutical Co., Ltd., analysts believe Protagonist Therapeutics, Inc. is more attractive than Takeda Pharmaceutical Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 PTGXProtagonist Therapeutics, Inc.8 1 0 -
Is TAK or PTGX More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.014, which suggesting that the stock is 98.579% less volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.264, suggesting its more volatile than the S&P 500 by 126.409%.
-
Which is a Better Dividend Stock TAK or PTGX?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 3.58%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or PTGX?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.7B, which are larger than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Takeda Pharmaceutical Co., Ltd.'s net income of $673.3M is higher than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 76.66x while Protagonist Therapeutics, Inc.'s PE ratio is 128.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.96x versus 24.99x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.96x 76.66x $7.7B $673.3M PTGXProtagonist Therapeutics, Inc.24.99x 128.68x $4.7M -$39.3M
-
Which has Higher Returns TAK or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 8.71% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of -99.41%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 1.63% beat Nxera Pharma Co., Ltd.'s return on equity of -19.06%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.54.43% $0.21 $79.7B SOLTFNxera Pharma Co., Ltd.73.58% -$0.55 $755.2M -
What do Analysts Say About TAK or SOLTF?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $19.07, signalling upside risk potential of 3.28%. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is TAK or SOLTF More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.014, which suggesting that the stock is 98.579% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.018, suggesting its less volatile than the S&P 500 by 98.16%.
-
Which is a Better Dividend Stock TAK or SOLTF?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 3.58%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or SOLTF?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.7B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $50.4M. Takeda Pharmaceutical Co., Ltd.'s net income of $673.3M is higher than Nxera Pharma Co., Ltd.'s net income of -$50.1M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 76.66x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.96x versus 2.47x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.96x 76.66x $7.7B $673.3M SOLTFNxera Pharma Co., Ltd.2.47x -- $50.4M -$50.1M
-
Which has Higher Returns TAK or STMM?
Stemcell Holdings, Inc. has a net margin of 8.71% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of --. Takeda Pharmaceutical Co., Ltd.'s return on equity of 1.63% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.54.43% $0.21 $79.7B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About TAK or STMM?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $19.07, signalling upside risk potential of 3.28%. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is TAK or STMM More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.014, which suggesting that the stock is 98.579% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TAK or STMM?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 3.58%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or STMM?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.7B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Takeda Pharmaceutical Co., Ltd.'s net income of $673.3M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 76.66x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.96x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.96x 76.66x $7.7B $673.3M STMMStemcell Holdings, Inc.0.17x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
